135 related articles for article (PubMed ID: 26313021)
1. Precision Medicine in Breast Cancer Care: An Early Glimpse of Impact.
Kurian AW; Friese CR
JAMA Oncol; 2015 Nov; 1(8):1109-10. PubMed ID: 26313021
[No Abstract] [Full Text] [Related]
2. Chemotherapy and the recurrence score--results as expected?
Pusztai L
Nat Rev Clin Oncol; 2015 Dec; 12(12):690-2. PubMed ID: 26552957
[No Abstract] [Full Text] [Related]
3. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Dinan MA; Mi X; Reed SD; Lyman GH; Curtis LH
JAMA Oncol; 2015 Nov; 1(8):1098-109. PubMed ID: 26313372
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer and genomic testing.
Liedtke C; Kolberg HC
Br J Surg; 2017 Jun; 104(7):799-801. PubMed ID: 28300277
[No Abstract] [Full Text] [Related]
5. [Gene signatures for breast cancer, clinical utility and therapeutic applications].
Vargas-Aguilar VM; Arroyo-Alvarez K
Rev Med Inst Mex Seguro Soc; 2018; 56(2):180-185. PubMed ID: 29906029
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer: updated guideline recommendations for HER2 testing.
Rakha EA; Ellis IO
Nat Rev Clin Oncol; 2014 Jan; 11(1):8-9. PubMed ID: 24322598
[TBL] [Abstract][Full Text] [Related]
7. Refining Treatment Decisions in Older Patients With Breast Cancer.
Flaum L; Gradishar WJ
JAMA Oncol; 2015 May; 1(2):166-7. PubMed ID: 26181016
[No Abstract] [Full Text] [Related]
8. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009.
Dinan MA; Mi X; Reed SD; Hirsch BR; Lyman GH; Curtis LH
JAMA Oncol; 2015 May; 1(2):158-66. PubMed ID: 26181015
[TBL] [Abstract][Full Text] [Related]
9. Genomic profile of breast cancer.
Plun-Favreau J; Svedman C; Valentine W; Rouzier R
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):393-4. PubMed ID: 25797274
[No Abstract] [Full Text] [Related]
10. Multigene prognostic tests in breast cancer: past, present, future.
Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer genomics: real-time use.
Bertucci F; Birnbaum D
Lancet Oncol; 2007 Dec; 8(12):1045-1047. PubMed ID: 18054870
[No Abstract] [Full Text] [Related]
12. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Turashvili G; Brogi E; Morrow M; Hudis C; Dickler M; Norton L; Wen HY
Breast Cancer Res Treat; 2017 Aug; 165(1):65-76. PubMed ID: 28577081
[TBL] [Abstract][Full Text] [Related]
13. In response: Genomic profile of breast cancer.
Seguí MA; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna S; Gracia A
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):395-7. PubMed ID: 25797142
[No Abstract] [Full Text] [Related]
14. Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature.
El Hage Chehade H; Wazir U; Mokbel K; Kasem A; Mokbel K
Am J Surg; 2018 Jan; 215(1):171-178. PubMed ID: 28622841
[TBL] [Abstract][Full Text] [Related]
15. Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.
Orucevic A; Heidel RE; Bell JL
Breast Cancer Res Treat; 2016 Jun; 157(3):427-35. PubMed ID: 27206678
[TBL] [Abstract][Full Text] [Related]
16. Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.
Seguí MÁ; Crespo C; Cortés J; Lluch A; Brosa M; Becerra V; Chiavenna SM; Gracia A
Expert Rev Pharmacoecon Outcomes Res; 2014 Dec; 14(6):889-99. PubMed ID: 25213317
[TBL] [Abstract][Full Text] [Related]
17. Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.
Schreuder K; Kuijer A; Rutgers EJT; Smorenburg CH; van Dalen T; Siesling S
Eur J Cancer; 2017 Oct; 84():270-277. PubMed ID: 28844015
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer multigene testing trends and impact on chemotherapy use.
Ray GT; Mandelblatt J; Habel LA; Ramsey S; Kushi LH; Li Y; Lieu TA
Am J Manag Care; 2016 May; 22(5):e153-60. PubMed ID: 27266581
[TBL] [Abstract][Full Text] [Related]
19. The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.
Kuchel A; Robinson T; Comins C; Shere M; Varughese M; Sparrow G; Sahu A; Saunders L; Bahl A; Cawthorn SJ; Braybrooke JP
Br J Cancer; 2016 Mar; 114(7):731-6. PubMed ID: 26954715
[TBL] [Abstract][Full Text] [Related]
20. Knowledge of genomic testing among early-stage breast cancer patients.
Richman AR; Tzeng JP; Carey LA; Retèl VP; Brewer NT
Psychooncology; 2011 Jan; 20(1):28-35. PubMed ID: 20200857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
